ETopical – Lifestyle
Home
Sample Page
Author:
Transgene S.A.
Transgene Provides Business and Financial Update for Q1 2026
April 29, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026
Availability of Transgene’s 2025 Universal Registration Document (URD)
April 9, 2026
Transgene to Participate in Upcoming Investor Meetings
April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 2, 2026
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
March 26, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
March 24, 2026